Intrasense: Erasmus University Medical Center Selects Myrian® for Its Pulmonology Core Lab
12 September 2014 - 2:25AM
Business Wire
Signature of 5-year agreement with
LungAnalysis
Regulatory News:
Intrasense (FR0011179886 – ALINS) (Paris:ALINS), a global leader
in multimodal medical imaging and oncology software, announces an
agreement with LungAnalysis, Erasmus Medical Center’s core lab
specialized in image analysis of lung diseases such as cystic
fibrosis (CF), bronchiectasis, severe asthma and others. Erasmus MC
is the largest Dutch university hospital and one of the top ten
best medical institutes in Europe according to the Times Higher
Education.
CF is a life shortening congenital disorder characterized by the
progressive development of bronchiectasis. According to the latest
WHO estimates (2004), currently 64 million people have COPD and 3
million people died of COPD. WHO predicts that COPD will become the
third leading cause of death worldwide by 20301. In 2011, 12.7
million American adults (aged 18 and over) were estimated to have
COPD, these being the third leading cause of death in America2.
Until recently, functional tests played the most important role
for diagnosis and monitoring of most lung diseases. Over the last
two decades, medical imaging (i.e. CT scanner) has been
increasingly used for the diagnosis and follow-up of these lung
diseases, for treatment planning and for the assessment of
treatment response.
Erasmus MC has been an Intrasense scientific partner in the
field of lung pathologies for several years. With this agreement,
it extends the use of Myrian® to new advanced research activities,
including academic clinical research, industry-sponsored trials and
even patient care.
“Myrian® perfectly matches our needs”, adds Pr. Tiddens,
Professor of Pediatric Respiratory Medicine at Erasmus University
Medical Center and Sophia Children's Hospital. “It is a reliable,
flexible and easy-to-use solution. The advanced and unique
capabilities of its clinical application Myrian® XP-Lung allows us
to measure specific imaging biomarkers. This is key for the optimal
evaluation of response to treatment in an accurate, reproducible
and timely manner. Over the years of our collaboration Intrasense
has been a very loyal partner adapting Myrian® to the needs of our
research.”
This collaboration validates Intrasense strategy and ability to
take advanced technology from clinical research to routine
radiology: “We are very happy about this agreement with one of the
most prestigious hospitals worldwide. It highlights Myrian®
pioneering ability to fulfill image-based needs in clinical care
and in clinical research”, comments Stéphane Chemouny, Intrasense
Scientific Director and Chairman.
1 http://www.who.int/respiratory/copd/en/2
http://www.lung.org/lung-disease/copd/resources/facts-figures/COPD-Fact-Sheet.html
About Erasmus
MC:Erasmus MC is the largest and most
authoritative scientific University Medical Center in the
Netherlands. Almost 13,000 staff members work within the core tasks
of patient care, education, and scientific research on the
continuous improvement and enforcement of individual patient care
and social healthcare. They develop high-level knowledge, pass this
on to future professionals, and apply it in everyday patient care.
Over the next five years, Erasmus MC wants to grow into one of the
best medical institutes in the world. Erasmus MC is part of the
Dutch Federation of University Medical Centers (NFU).
For information about Erasmus MC, please visit
www.erasmusmc.nl.
About
Intrasense:Created in 2004 with an innovative
technology of tissues detection in CT scan, Intrasense designs,
develops and markets Myrian®, a unique, vendor-neutral software
suite for the visualization and advanced processing of multimodal
medical images such as MRI, CT scans, PET, X-rays, and more.
Developed with leading academic and scientific partners, Myrian®
combines and uses all of the various medical images to extract
information vital to the patient's care, to evaluate treatment
efficiency and to assess drug candidates in oncology and other
pathologies. With more than 700 client sites around the world,
Myrian® has been certified as a "medical device" in over 40
countries including the United States (FDA), Europe (CE) and Asia.
Intrasense SA is listed on the Alternext (FR0011179886 - ALINS).
The company employs 70 people, including 25 dedicated in R&D.
Labelled “innovative company” by Oseo, Intrasense has invested over
9 M€ in R&D since its creation.For more about Intrasense,
please visit www.intrasense.fr and follow us on LinkedIn.
IntrasensePatrick MayetteChief Executive
OfficerChristophe LamboeufChief Financial
OfficerPhone: (33) (0)1 48 04 32
83investor@intrasense.frorNewCapFinancial disclosure and
investor relationsValentine Brouchot / Pierre LaurentPhone:
(33) (0)1 44 71 94 96intrasense@newcap.fr
Intrasense (EU:ALINS)
Historical Stock Chart
From Nov 2024 to Dec 2024
Intrasense (EU:ALINS)
Historical Stock Chart
From Dec 2023 to Dec 2024
